Navigation Links
Breast Cancer Action Sues to End Gene Patenting
Date:5/12/2009

Lawsuit Seeks Increased Access to Information for Patients of Breast Cancer

SAN FRANCISCO, May 12 /PRNewswire-USNewswire/ -- Breast Cancer Action (BCA) is challenging the legality of patenting human "breast cancer genes." BCA is joining the American Civil Liberties Union in suing Myriad Genetics (a private biotechnology company based in Utah), that currently holds the patent on the two human genes known as BRAC1 and BRAC2.

The BRAC1 and BRAC2 genes are present in every human. However, people with certain genetic mutations on these genes are at an increased risk of developing breast and ovarian cancer. Myriad holds exclusive rights to these genes and their mutations and to the research performed on them. Testing for the BRAC1 and BRAC2 mutations can only be performed at Myriad labs and currently costs over $3,000.

Since 1998, when BRAC1 & 2 were first patented, BCA has maintained that the patenting of human genes interferes with patients' access to genetic testing and medical care.

"The time has finally arrived for the courts to decide who owns our genes," said Barbara Brenner, executive director of Breast Cancer Action.

When one company controls all the testing, less information and resources are available to both patients and researchers. Women unable to afford the $3,500 fee are prevented from access to the test; women seeking second opinions on any results they might receive have nowhere to go; and women of African, Hispanic, or Asian decent are at a significant disadvantage because they disproportionately receive ambiguous results when tested by Myriad.

"There are so many injustices and inequities in breast cancer," Brenner said. "The time has come to address them in all their forms -- as they affect genetic risk, as well as social, political, and economic realities. This case is an important first step."

BCA joins this litigation in hopes that it will open doors to better research and information, and ultimately better health care for women regardless of their economic situation or their racial background.

The case, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al., is filed in the U.S District Court for the Southern District of New York.

Breast Cancer Action (www.bcaction.org) -- is a non-profit education and advocacy organization that does not accept funding from pharmaceutical companies or any other organizations that profit from or contribute to the breast cancer epidemic.


'/>"/>
SOURCE Breast Cancer Action
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics
2. ACLU Challenges Patents on Breast Cancer Genes
3. Scientists identify gene in breast cancer pathway
4. MultiVu Video Feed: REESE WITHERSPOON JOINS AVON FOUNDATION FOR WOMEN AND SAN FRANCISCO GENERAL HOSPITAL TO CELEBRATE 5TH ANNIVERSARY OF AVON COMPREHENSIVE BREAST CENTER
5. Video: Reese Witherspoon Joins Avon Foundation for Women and San Francisco General Hospital to Celebrate 5th Anniversary of Avon Comprehensive Breast Center
6. HealthCentral.com Collaborates With BreastCancer.org, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online
7. Park Meadows Cosmetic Surgery, a Pioneer in DIEP Flap Breast Reconstruction Surgery in Colorado, Introduces New, Informative Website
8. International Breast Milk Project Helps Mothers Worldwide
9. New technique may help detect potential breast cancer spread
10. Breast Cancer Network of Strength(R) and SCA Personal Care North America, Through Its TENA(R) Brand, Team Up to Offer Support to Women Affected by Breast Cancer
11. Genes Linked to Spread of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... PA (PRWEB) , ... February 17, 2017 , ... Butler ... about the Stannah Stairlift and other Butler products. Ken was impressed with the ... and agreed to endorse the product on his show. This endorsement by Ken ...
(Date:2/18/2017)... ... February 18, 2017 , ... A ... information and contact points to easily connect elderly veterans of America's armed forces ... elder-care funding. It also conveys material on this year's increase in the Veterans ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells ... the electronic prescribing of controlled and non-controlled substances plus the ability to manage ... in the United States now accept electronic prescriptions, according to the Office of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive ... FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... and preventive action (PA)? , The methods share techniques and tools but they ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue ... that Karen Pilley has been promoted to Chief Executive Officer. , The ... paradigm – a shift that demands the transition from pay-for-service to pay-for-performance models. ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
(Date:2/16/2017)...  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ) ... that executive management will participate in the RBC Capital ... 2017. Adrian Adams , Chief Executive Officer, will ... local time on Wednesday, February 22, 2017. ... may be accessed from the Investors section of the ...
(Date:2/16/2017)... Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... announced that Vincent J. Angotti has ... of the company,s board of directors, effective Monday, ... decades of experience leading executive and commercial teams ...
Breaking Medicine Technology: